BR112022021511A2 - Composição de pó seco para administração peroral - Google Patents

Composição de pó seco para administração peroral

Info

Publication number
BR112022021511A2
BR112022021511A2 BR112022021511A BR112022021511A BR112022021511A2 BR 112022021511 A2 BR112022021511 A2 BR 112022021511A2 BR 112022021511 A BR112022021511 A BR 112022021511A BR 112022021511 A BR112022021511 A BR 112022021511A BR 112022021511 A2 BR112022021511 A2 BR 112022021511A2
Authority
BR
Brazil
Prior art keywords
average diameter
weight
volume
dry powder
composition
Prior art date
Application number
BR112022021511A
Other languages
English (en)
Portuguese (pt)
Inventor
Camber Ola
Everaert Arnout
Grudén Stefan
Original Assignee
Vicore Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma Ab filed Critical Vicore Pharma Ab
Publication of BR112022021511A2 publication Critical patent/BR112022021511A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022021511A 2020-04-24 2021-04-23 Composição de pó seco para administração peroral BR112022021511A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2006079.4A GB202006079D0 (en) 2020-04-24 2020-04-24 New composition
PCT/GB2021/050994 WO2021214488A1 (en) 2020-04-24 2021-04-23 New dry powder composition for peroral administration

Publications (1)

Publication Number Publication Date
BR112022021511A2 true BR112022021511A2 (pt) 2023-01-24

Family

ID=71080269

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021511A BR112022021511A2 (pt) 2020-04-24 2021-04-23 Composição de pó seco para administração peroral

Country Status (19)

Country Link
US (2) US11844868B2 (cg-RX-API-DMAC7.html)
EP (2) EP4138790B1 (cg-RX-API-DMAC7.html)
JP (3) JP7387903B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230005220A (cg-RX-API-DMAC7.html)
CN (1) CN115697309A (cg-RX-API-DMAC7.html)
AU (2) AU2021260923B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022021511A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180646A1 (cg-RX-API-DMAC7.html)
DK (1) DK4138790T3 (cg-RX-API-DMAC7.html)
ES (1) ES2976885T3 (cg-RX-API-DMAC7.html)
GB (1) GB202006079D0 (cg-RX-API-DMAC7.html)
IL (1) IL297373B2 (cg-RX-API-DMAC7.html)
LT (1) LT4138790T (cg-RX-API-DMAC7.html)
MX (1) MX2022013070A (cg-RX-API-DMAC7.html)
PL (1) PL4138790T3 (cg-RX-API-DMAC7.html)
PT (1) PT4138790T (cg-RX-API-DMAC7.html)
SI (1) SI4138790T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021214488A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211460B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
KR20240148359A (ko) 2022-02-10 2024-10-11 바이코어 파마 아베 특발성 폐섬유증 치료를 위한 불록시부티드의 용도
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
WO2005123072A1 (en) 2004-06-14 2005-12-29 Sepracor Inc. Methods and compositions for the treatment of pulmonary diseases
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP2091539A1 (en) * 2006-12-12 2009-08-26 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
CA2821985C (en) * 2011-01-11 2019-07-09 Dimerix Bioscience Pty Ltd Combination therapy
HK1244232A1 (zh) 2015-03-02 2018-08-03 维科尔药物公司 用於治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
US11931341B2 (en) * 2018-03-22 2024-03-19 University Of Lowa Research Foundation Compositions and methods for the treatment and prevention of muscular dystrophy
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Also Published As

Publication number Publication date
EP4138790B1 (en) 2024-01-31
ES2976885T3 (es) 2024-08-12
JP2024020417A (ja) 2024-02-14
US20220202726A1 (en) 2022-06-30
JP2023503178A (ja) 2023-01-26
ZA202211460B (en) 2025-02-26
EP4138790A1 (en) 2023-03-01
KR20230005220A (ko) 2023-01-09
WO2021214488A1 (en) 2021-10-28
US11844868B2 (en) 2023-12-19
US20240269081A1 (en) 2024-08-15
EP4389212A2 (en) 2024-06-26
US12605341B2 (en) 2026-04-21
JP2026099828A (ja) 2026-06-18
MX2022013070A (es) 2022-11-30
AU2021260923A1 (en) 2022-12-08
PT4138790T (pt) 2024-04-01
CN115697309A (zh) 2023-02-03
PL4138790T3 (pl) 2024-06-10
SI4138790T1 (sl) 2024-05-31
AU2021260923B2 (en) 2026-03-12
LT4138790T (lt) 2024-04-10
IL297373A (en) 2022-12-01
GB202006079D0 (en) 2020-06-10
IL297373B2 (en) 2026-05-01
EP4389212A3 (en) 2024-10-09
CA3180646A1 (en) 2021-10-28
DK4138790T3 (en) 2024-03-11
IL297373B1 (en) 2026-01-01
AU2026203700A1 (en) 2026-05-28
JP7387903B2 (ja) 2023-11-28

Similar Documents

Publication Publication Date Title
ES2754388T3 (es) Composiciones y métodos de dicetopiperazina microcristalina
JP7366385B2 (ja) ヘルペスウイルス誘発疾患の処置のための方法および組成物
KR102058097B1 (ko) 다루나비어 복합 제제
BR112015021814A2 (pt) aglomerados respiráveis de partículas carreadoras porosas e fármaco micronizado
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
BR112015028644A2 (pt) composições de cenicriviroc e métodos de criação e uso do mesmo
CN104902905A (zh) 药物组合物
BR112022021520A2 (pt) Composição de liberação atrasada para administração peroral
ES2598823T3 (es) Formulaciones de darunavir
MX2022013070A (es) Nueva composición en polvo seco para administración peroral.
PT1545634E (pt) Método para preparar composições de pó seco para inalação
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
KR20220034736A (ko) 히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법
BR112015020443A8 (pt) formulação em pó para inalação, seus usos e seu processo de preparação, e composição farmacêutica
TW202128169A (zh) 具有降低副作用之hdac治療劑量
WO2017028660A1 (zh) 一种含有喹啉衍生物或其盐的药物组合物
BR112012005127B1 (pt) Composição anti-helmíntica na forma de um grânulo estável, sistema de dosagem para dosar oralmente animais com um agente anti-helmíntico, método de preparação de uma formulação de entrega de líquido estável para tratar um animale método para formar uma composição de antihelmíntico
UA82268C2 (uk) Гранули, що містять гідрохлорид венлафаксину, та спосіб їх виготовлення
ES2383005T3 (es) Medicamentos para enfermedades glomerulares
EA026665B1 (ru) Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением
RU2013141446A (ru) Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
JP2018027912A (ja) オセルタミビルリン酸塩含有医薬組成物
CN114903915A (zh) 二氧化铈纳米材料在抑制冠状病毒中的应用
JP2016147817A (ja) 経口投与用粒状造粒製剤
JP6616968B2 (ja) 医薬組成物

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]